Revenue rose by 6.0% y-o-y to RMB85.4 million as revenue for primary healthcare and laboratory services rose, offsetting the lower revenue from the company’s distribution of dental equipment and supplies. Revenue from the primary healthcare segment rose by 12.5% y-o-y to RMB57.0 million as it saw an overall increase in patients seeking dental treatment while revenue from laboratory services rose by 20.5% y-o-y to RMB10.8 million due to business expansion to overseas markets. Meanwhile, revenue from distribution of dental equipment and supplies fell by 15.8% y-o-y to RMB17.7 million due to lesser demand for dental equipment from government hospitals on the back of a reduction in government capital expenditure budget.
Shares in Aoxin Q&M (SGX:1D4
) opened higher on Aug 12 after the company reported a profit of RMB7.3 million ($1.3 million) for the 1HFY2024 ended June 30, reversing from the loss of RMB1.2 million in the same period the year before. As at 9.38am, shares in Aoxin Q&M were trading at 6.8 cents, 30.8% higher than its last-closed price of 5.2 cents on Aug 8.
On July 31, Aoxin Q&M said it expected to see a “significant overall improvement” in its results for the six-month period.
